AMD EPYC Processors Deployed with Over 2 Petaflops of Computing Power – I-Connect007

AMD and Okinawa Institute of Science and Technology Graduate University (OIST) , announced the deployment of AMD EPYC 7702 processors for use in a new, high performance computing system. The EPYC processor-based supercomputer will deliver the 2.36 petaflops of computing power OIST plans to use for scientific research at the University.

The Scientific Computing & Data Analysis Section (SCDA) of OIST plans to implement the new supercomputer for supporting OIST computationally intensive research ranging from bioinformatics, computational neuroscience, and physics. SCDA adopted AMD EPYC after significant growth, including a 2X increase in users.

2020 is a milestone year for OIST with new research units expanding the number of research areas. This growth is driving a significant increase in our computational needs, said Eddy Taillefer, Ph.D., Section Leader, Scientific Computing & Data Analysis Section. Under the common resource model for which the computing system is shared by all OIST users we needed a significant increase in core-count capacity to both absorb these demands and cope with the significant growth of OIST. The latest AMD EPYC processor was the only technology that could match this core-count need in a cost-performance effective way.

Key factors of OISTs selection of the AMD EPYC processors included superior cost-performance, memory/PCIe bandwidth, and high core counts per server. OIST plans to also consider EPYC processors for other growing computational needs for University researchers in the future.

AMD is proud to be working with leading global institutions to bring scientific research to the forefront through the power of high performance computing technology, said Ram Peddibhotla, corporate vice president, EPYC product management, AMD. With high performance capabilities, ease of management and scalability, 2ndGen AMD EPYC processors can assist OIST researchers with advancing technological innovations and supporting their research goals in bioinformatics, computational neuroscience, and physics.

Excerpt from:
AMD EPYC Processors Deployed with Over 2 Petaflops of Computing Power - I-Connect007

Former Ghoraghat UNO Wahida Khanam, who was critically injured in an attack, comes out of the National Institute of Neuroscience and Hospital (NINH)…

Vendor Information

Editor: A.M. MUFAZZAL, Managing Editor: ARSHAD HOSEIN. Printed and published by MAINUL HOSEIN from the New Nation Printing Press. The New Nation, 1 R.K. Mission Road,Ittefaq Bhaban (3rdfloor), Dhaka-1203, Bangladesh,Phones: PABX: 47115875, 47115879, 47114514,Fax : 880-2-47115865, Email: For News: n_editor@bangla.net, n_news@bangla.net,For Advertisement nnation@bangla.net

View post:
Former Ghoraghat UNO Wahida Khanam, who was critically injured in an attack, comes out of the National Institute of Neuroscience and Hospital (NINH)...

New programme explores the vital role of education and awareness in prevention and management of allergies, anaphylaxis and rare diseases -…

The British Society of Allergy and Clinical Immunology (BSACI) and ITN Productions Industry News have co-produced a news-style programme raising awareness and education around allergies, anaphylaxis, clinical immunology and rare diseases to help improve health outcomes and prevent the tragic loss of life.For those living with life threatening food allergies, compromised respiratory functions or immune systems, the misinformation surrounding allergies and the current pandemic crisis is especially concerning. The risk of anaphylaxis due to severe allergies means for many, returning to a new normal after lockdown will be a particularly anxious time. Anchored by ITN Productions Industry News presenter Samantha Simmonds, Allergy and Clinical Immunology Attention Needed! explores the latest advancements in prevention and management of allergies, in particular food allergies, anaphylaxis and rare diseases often mistaken for an allergy. The programme hears from families who have lost loved ones to anaphylaxis and how the devastating deaths could have been avoided. Passionate about bringing change to prevent further loss of life, BSACI highlights the importance of greater awareness, education and training in schools and society, clearer messaging and information across food packaging and restaurant menus and the importance of checking dates on life-saving medication as some of the fundamental factors critical to improving outcomes.Launching at the British Society for Allergy and Clinical Immunology's Annual Digital Conference on 2 October 2020, the programme will form part of an extensive awareness campaign. Professor Adam Fox, President of BSACI said: Sadly people are dying in the UK as a result of their allergies, these deaths could have been prevented had appropriate safeguards been put in place. Our aim is to raise awareness of allergies and the impact these have on the everyday lives by working with patients and decision makers to bring about change.Elizabeth Fisher-Robins, Head of ITN Productions Industry News said: Were delighted to be partnering with the British Society of Allergy and Clinical Immunology to produce a programme to help raise awareness of the need for greater education and awareness of allergies and anaphylaxis. The current pandemic has caused increasing challenges for those living with allergies and we hope the films will provide a platform to stimulate discussion and advance solutions and policy.The programme features key interviews and reports with sponsored editorial profiles from the following leading companies:

Mylan NovartisTakedaMast Cell Action

Allergy and Clinical Immunology Attention Needed! can be viewed directly here via the BSACI website

For further information please contact Fiona Rayner at BSACI 0207 501 3910 or email info@bsaci.org

-Ends-About ITN Productions Industry NewsITN Productions produces bespoke creative and commercial content for broadcasters, businesses, brands, rights holders and digital channels. Industry News forms part of this offering and is a communications tool for leading industry bodies and national associations produced in a broadcast news-style programme format, including interviews, news items and sponsored editorial profiles. For more information visit: ITN Productions

About the British Society of Allergy and Clinical ImmunologyThe BSACI began life as a small interest group for allergists but has grown to become a major force in medicine in the UK with over 900 members working across many medical specialities including allergy, immunology and paediatrics, ENT, dermatology, respiratory medicine and primary care.The BSACI is the national, professional and academic society which represents the specialty of allergy at all levels. Its aim is to improve the management of allergies and related diseases of the immune system in the United Kingdom, through education, training and research. One of the BSACI's main activities is the formulation of National Guidelines for use by allergy specialists. The process used by the BSACI to develop these guidelines has been accredited by NICE. For more information visit: BSACI website

See the original post here:
New programme explores the vital role of education and awareness in prevention and management of allergies, anaphylaxis and rare diseases -...

Akiko Iwasaki and Gregg Gonsalves named among 50 experts to trust in a pandemic – Yale Daily News

Yale Medicine

Yale Professor of Immunology Akiko Iwasaki and Assistant Professor of Epidemiology Gregg Gonsalves 11 GRD 17 were named on the 50 experts to trust in a pandemic list. The list, curated by editors of the health and wellness publication Elemental, presents 50 professionals that people should follow on social media for evidence-based guidance during the pandemic.

According to the website for Elemental, the list promotes trustworthy sources to help the general public avert the pitfalls of misinformation while staying up-to-date with COVID-19 developments. Among the experts included are Director-General of the World Health Organization Tedros Adhanom Ghebreyesus, founder and director of Scripps Research Translational Institute Eric Topol and former director of the Centers for Disease Control and Prevention Tom Frieden.

Jeremy Faust, an emergency physician at Brigham and Womens Hospital and instructor at Harvard Medical School, was also featured in the list. Faust recently founded Brief 19 a project that provides readers with a daily recap of new information pertaining to the pandemic. He told the News that because so much about the pandemic is being politicized, physicians, scientists and public health experts should serve as a nonpartisan voice of reason for people to use as resources.

Our job as public health and research experts is to contextualize news in a way thats accurate and that doesnt increase hype and panic without the need to do so, Faust said. But also on the flipside, not to downplay when things are serious.

According to Faust, following experts on social media gives people access to balanced views and important context that mainstream outlets usually do not discuss, such as the research methods behind the discoveries that make the headlines, in addition to their reliability.

In an email to the News, Iwasaki wrote that she was delighted to be part of the list. She also added that she feels a strong sense of duty as a scientist to provide a knowledgeable perspective surrounding what has been discovered and what remains unknown about COVID-19. Iwasaki told the News that access to experts opinions allows people to make more informed decisions, making it fundamental for scientists to communicate their thoughts to a wider audience.

There is a lot of sensational media coverage out there that is either misinformation or mis-guided information, Iwasaki wrote. I want to provide a voice from my scientific expertise in immunology.

Iwasakis lab at the Yale School of Medicine explores how immunity is initiated and sustained. As someone who is at the forefront of COVID-19 research, she has been featured in news outlets across the globe and is an active voice within the scientific realm of Twitter. In addition to being a professor at Yale, Iwasaki is also a principal investigator at the Howard Hughes Medical Institute.

In her case, Iwasaki said that she relies on experts in fields such as epidemiology, modeling and health policy to illuminate what the media is reporting on with a professional viewpoint.

With so many opinions flying around the internet, it is important for me to hear what the experts have to say on important issues for COVID-19 transmission and control, Iwasaki wrote.

Although Gonsalves did not respond to requests for comments from the News, he tweeted that he was honored even to be named in the same sentence as Dr. Iwasaki. He also added that he took Iwasakis immunobiology course when he was an undergraduate student at Yale, and that, as a colleague, she is a role model for [him] and many on how to be an ethical, caring scientist and academic.

Gonsalves was an HIV/AIDS activist for over 30 years and currently works with infectious disease epidemiology. In addition to being a professor at the Yale School of Public Health, he is also an associate professor of Law at the Yale Law School.

Hanna Ehrlich GRD 22, a doctoral student at the School of Public Health and a fellow at the Global Health Justice Partnership, wrote in an email to the News that those who are unfamiliar with epidemiology can often dismiss the importance of history in the translation and practice of science in society. However, she wrote, Gonsalves has been through this before, fighting for accessible science in the face of myriad political obstacles during the AIDS epidemic in the 1990s.

On campus, Gonsalves spearheads initiatives including the Global Health Justice Partnership which focuses on the cross section between global health, human rights and social justice and the Collaboration for Research Integrity and Transparency which aims to improve the quality and transparency of evidence behind medical products. On Twitter, Gonsalves has also been active in debunking misinformation and exposing those who distort scientific and public health guidance for political or ulterior motives.

Gregg calls out B.S. like no one else, Ehrlich wrote. But he also acknowledges the limitations and strengths of scientific evidence, giving his audience more agency than others might.

According to Elizabeth White GRD 22, who is also a doctoral student at the School of Public Health and fellow at the GHJP, Gonsalvess career both in HIV/AIDS activism and as a professor has largely centered on how political systems can engender structural inequities and health disparities.

In Gonsalves course Political Epidemiology, White says that he teaches students how to methodically analyze the impact of policy decisions on population health outcomes, especially for infectious diseases such as HIV. To White, his course shapes students into educated consumers of studies.

White also wrote that one of Gonsalves greatest strengths as teacher, public health leader and Twitter communicator is that he tells it like it is, based on data and his wealth of experiences.

Iwasaki told the News that while professional perspectives are important, it can be dangerous for people to speak with authority on areas that do not fall within their own field of expertise. Iwasaki said that she knows for herself the boundaries of [her] expertise and knowledge and will only speak of what [she is] capable of evaluating.

Iwasaki also commented on a lack of diverse representation in the media when it comes to spotlighting scientific experts.

Women and people of color are not being well represented as experts speaking on social and traditional media, Iwasaki wrote. This unfortunately turns the clock backwards on any progress we were making before the pandemic for what a scientist looks like. For this reason, I feel even more committed to speaking to the media and through social media to disseminate scientific truth.

Iwasaki did tell the News, however, that she believes that the 50 experts list did a great job in representing a diverse group of scientists.

Hannah Ro 22 told the News that she started following Iwasaki on Twitter during the pandemic and enjoys keeping up with the research she shares. To Ro, who is enthusiastic about science and public health, Iwasaki is a role model.

When I see Dr. Iwasaki on Twitter and on the news Im really inspired, Ro said, First of all because shes a woman and second of all because shes Asian, and for me to see an Asian woman being a leader in her field is just really cool.

As of Oct. 1, there have been 7.3 million diagnosed cases of COVID-19 in the United States.

Maria Fernanda Pacheco | maria.pacheco@yale.edu

Link:
Akiko Iwasaki and Gregg Gonsalves named among 50 experts to trust in a pandemic - Yale Daily News

Government COVID-19 testing lab to open at the University of Birmingham – University of Birmingham

The addition of the lab will make Birmingham the first university campus in the UK with end to end pillar two testing capabilities.

As part of the drive to expand COVID-19 testing capacity across the UK, The University of Birmingham has been announced today as one of the first academic sector lab partnerships to come online. The lab, based at the University of Birminghams Medical School, will form part of NHS Test and Trace, joining Britains largest network of diagnostic testing facilities increasing coronavirus testing capacity.

The new facilities will help to increase sample processing capacity, with the number of tests that can be processed gradually increasing over the coming months. The Birmingham lab will be the first of the new facilities to open, delivering over 3,000 tests per day over the coming months.

Set up by a multi-disciplinary team from the Institutes of Immunology and Immunotherapy and Microbiology and Infection, the lab will be headed up by infectious disease expert Professor Alan McNally, who will manage a team of over 40 lab staff, many of whom have been recruited to support the facility. Professor McNally has already played a significant role in the fight against COVID-19 having been seconded into the role of Infectious Disease Lead at the governments first flagship Lighthouse Lab in Milton Keynes.

Professor McNally said: Im thrilled to be involved with this next phase of the governments national testing programme. What has been achieved in establishing this lab in such a short space of time is testament to the dedication of the team at the University who have worked tirelessly to ensure we are in a position to begin processing samples as soon as next week.

Professor Alex Richter from the Universitys Institute of Immunology and Immunotherapy, who has played an integral role in setting up the lab from logistics to the recruitment and training of lab staff, said: This has been a huge team effort, drawing on all our resources, retraining staff from the University of Birminghams Clinical Immunology Service, Estates, Finance, Human resources and IT departments and collaborating with University Hospitals Birmingham virologists.

Professor David Adams, Head of the College of Medical and Dental Sciences said: From ground breaking research to the selflessness of our staff and students who mobilised to support our local community and the NHS, the University has made important contributions to both the national and the global COVID effort. The opening of this new lab is only possible because we havespecialist facilitiesand particularly highly skilled anddedicated staff who want to contribute to thewider national response to COVID-19.

The lab will work in parallel to the recently launched on-campus community testing site located at the Southgate entrance, which opened in early September. The testing site is open to staff, students and the local communityand offers testing for anyone with coronavirus symptoms. The addition of the lab will make Birmingham the first university campus in the UK with end to end pillar two testing capabilities.

For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.

Filming/photography requests or requests for interview should be directed to pressofficenewsdesk@dhsc.gov.uk

About the University of Birmingham

The University of Birmingham is ranked amongst the worlds top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.

More here:
Government COVID-19 testing lab to open at the University of Birmingham - University of Birmingham

Beyond Air to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor…

GARDEN CITY, N.Y., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO for the treatment of solid tumors and tumor metastases, today announced that a virtual poster presentation has been accepted for the AACR Conference on Tumor Immunology and Immunotherapy, which is being held from October 19th to 20th.

Virtual Poster Video Presentation at the AACR Tumor Immunology and Immunotherapy Conference:

About Beyond Air, Inc.Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit for clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit http://www.beyondair.net.

About Nitric Oxide (NO)Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.

About Solid Tumors Cancer is the second leading cause of death globally, with tumor metastases responsible for approximately 90% of all cancer-related deaths. Current cancer treatment modalities generally include chemotherapy, immunotherapy, radiation, and/or surgery. Nitric oxide at high concentrations has been reported to show anticancer properties and to serve as a chemosensitizer and radiotherapy enhancer. Based on its current findings, Beyond Air is developing treatment protocols using ultra-high nitric oxide concentrations to ablate primary tumors and treat metastatic disease.

Forward Looking StatementsThis press release contains forward-looking statements concerning inhaled nitric-oxide and the Companys LungFit product, including statements with regard to potential regulatory developments, the potential impact on patients and anticipated benefits associated with its use. Forward-looking statements include statements about our expectations, beliefs, or intentions regarding our product offerings, business, financial condition, results of operations, strategies or prospects. You can identify such forward-looking statements by the words anticipates, expects, intends, impacts, plans, projects, believes, estimates, likely, goal, assumes, targets and similar expressions and/or the use of future tense or conditional constructions (such as will, may, could, should and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel devices and drugs, which is unproven and may never lead to marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in various stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history and other risks identified and described in more detail in the Risk Factors section of the Companys most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

CONTACTS:Steven Lisi, Chief Executive Officer Beyond Air, Inc.Slisi@beyondair.net

Corey Davis, Ph.D.LifeSci Advisors, LLCcdavis@lifesciadvisors.com (212) 915-2577

Read more:
Beyond Air to Present Data on Nitric Oxide in the Treatment of Solid Tumors at the American Association for Cancer Research (AACR) Conference on Tumor...

Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and…

SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)--Sonoma Biotherapeutics, a privately held company developing regulatory T-cell (Treg) therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million. Investors participating in the round include Lyell Immunopharma, ARCH Venture Partners, 8VC, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Alexandria Venture Investments, the JDRF T1D Fund and additional undisclosed investors.

Sonoma also announced three new appointments to the senior management team: Leonard Dragone, M.D., Ph.D., joins as chief medical officer; Sejal Hall, Ph.D., joins as vice president of portfolio, program and alliance management; and Susan Lacy, Ph.D., joins as vice president of discovery. They join an experienced team steeped in next-generation research, development and manufacturing capabilities in immunology, cell therapy and genetic engineering.

We have made significant progress in a short amount of time in our mission to move adoptive cell therapy beyond cancer and into other disease areas, including autoimmunity and neuroinflammation, said Co-Founder and CEO Jeffrey Bluestone, Ph.D. Our progress in applying cell therapy to reprogram the immune system to alter the course of disease has attracted the attention and the vision of talented scientists and drug developers, as well as proven investors.

This expansion of the Sonoma team and the Series A financing will enable Jeff and the rest of the organization to continue their great progress, said Dr. Rick Klausner, executive chairman of Lyell Immunopharma and chair of the Sonoma Biotherapeutics board of directors. They are well poised to drive the next generation of cell therapy forward to advance treatments and potentially cures for patients with significant unmet medical need.

About Treg Cell Therapy

The goal of Treg therapy is to restore a state of self-tolerance by halting harmful inflammatory responses in autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis, along with degenerative diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimers. Over 50 million Americans currently live with an autoimmune disease, and millions more with some form of degenerative disease. For many, existing therapies are ineffective at controlling their disease.

Treg cells have a clear role in many of these conditions. These cells natural ability to migrate to inflamed tissues and control harmful immune responses makes them ideal for treating a range of conditions. In addition, the ability to engineer Treg cells to target specific disease-causing antigens reduces the potential for unwanted systemic effects. The role of Treg cells in tissue maintenance and repair offers the potential for effective, durable and restorative treatments.

About Sonoma Biotherapeutics

Sonoma Biotherapeutics is a South San Francisco and Seattle-based company leading the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies. More information at http://www.sonomabio.com.

See the original post:
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and...

AAAAI’s School Asthma and Allergy Bill Passes the House of Representatives – PR Web

"The School-Based Allergies and Asthma Management Program Act (H.R. 2468) is important to encourage and support states in making sure schools have in place a comprehensive school-based allergies and asthma management program." - AAAAI President Mary Beth Fasano, MD, MSPH, FAAAAI

MILWAUKEE (PRWEB) September 29, 2020

The School-Based Allergies and Asthma Management Program Act (H.R. 2468), a bill supported by the American Academy of Allergy, Asthma & Immunology (AAAAI) that is based on the AAAAIs School-based Asthma Management Program (SAMPRO), has passed the House of Representatives by a voice vote and will now move on to the Senate for consideration. This bill would encourage schools receiving asthma-related grants to have trained personnel and a comprehensive school-based allergies and asthma management program. House Energy and Commerce Committee Chairman Frank Pallone (D-NJ), Ranking Member Greg Walden (R-OR), House Majority Leader Steny Hoyer (D-MD), and Phil Roe, MD (R-TN) spoke in support of the bill.

H.R. 2468, which is sponsored by Majority Leader Hoyer and Rep. Roe, MD, was joined by more than 40 co-sponsors. It is widely supported by additional healthcare and patient organizations, including the American College of Allergy, Asthma, and Immunology; the Asthma and Allergy Foundation of America; the Allergy and Asthma Network; and the National Association of School Nurses.

As schools reopen and students return to the classroom, the School-Based Allergies and Asthma Management Program Act (H.R. 2468) is important to encourage and support states in making sure schools have in place a comprehensive school-based allergies and asthma management program, said AAAAI President Mary Beth Fasano, MD, MSPH, FAAAAI.

H.R. 2468 was developed in conjunction with the AAAAI in support of SAMPRO. Launched by the AAAAI in 2016, SAMPRO details the elements necessary for the education of children, families, clinicians, and school-based personnel based on a circle of support that enhances multidirectional communication and promotes better care for children with asthma within the school setting.

Americas students ought to be able to go to school and learn without having to worry that school nurses and staff wont be prepared to help in an emergency relating to asthma or allergies. Parents should have peace of mind that their childrens schools are equipped to handle an asthma attack or an allergic reaction. This legislation will help by encouraging more schools around the country to have the proper training and planning in place, said Majority Leader Hoyer upon the passing of the bill.

In the U.S. there are about six million children under 18 who have been diagnosed with asthma. It is critical our schools are prepared to understand and address this condition to maintain student safety. The School-Based Allergies and Asthma Management Program Act will help school personnel and parents ensure students with asthma and other allergies adequately manage their condition so they can focus on their education with peace of mind, added Rep. Roe, MD.

The AAAAI will work with the bill sponsors to urge the Senate to pass the legislation before the end of the year so the bill can become law.

You can learn more about SAMPRO on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAIs Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

###

Share article on social media or email:

See the rest here:
AAAAI's School Asthma and Allergy Bill Passes the House of Representatives - PR Web

Dutch Vico Therapeutics Strengthens Leadership Team with the Appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent…

LEIDEN, The Netherlands, October 01, 2020 / B3C newswire / --Vico Therapeutics,a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced the appointment of Rupert Sandbrink, M.D., Ph.D., as the companys chief medical officer and Anders Hinsby, Ph.D., as independent Director.

We are very excited to welcome Rupert as our CMO, as he brings a wealth of clinical development and regulatory experience to the team as we prepare for our first in human trials. Anders is a great addition to our Board of Directors given his experience from Orphazyme, said Luc Dochez, Founder and Chairman of Vico Therapeutics.

Dr. Sandbrink has over twenty years of experience spanning all stages of clinical development, from first-in-human studies to product launches. Prior to joining Vico, Dr. Sandbrink has held many senior positions, most recently as Chief Development & Chief Medical Officer, at Topas Therapeutics GmbH. Before that he was Executive Vice President, Multiple Sclerosis/Neurology & Immunology at Forward Pharma A/S and a member of Forwards Executive Management Team. At Bayer he was Vice President, Head Experimental Medicine Women's Health & Common Mechanism Research, and he also served as Vice President, Head Global Clinical Development Neurology, Ophthalmology, Haematology, Immunology. At Bayer, Dr. Sandbrink led the clinical development programs for multiple small molecules and biologics, including Eylea, Betaferon, Lemtrada, and Kovaltry.

Dr. Sandbrink is a Board-certified clinical pharmacologist and received his Ph.D. in molecular biology and his medical degree from the Ruprecht-Karls-Universitt Heidelberg. He completed the Advanced Management Program at the IESE Business School and is also a lecturer and guest scientist at the Heinrich-Heine-Universitt Dsseldorf, Department of Neurology. He is the author of more than 80 peer-reviewed scientific and review articles.

I am delighted to join the highly experienced team at Vico to discover, develop and deliver therapies for rare CNS disorders, and I am looking forward to bringing Vicos lead compound to the clinic for the benefits of patients suffering from these progressive and potentially fatal neurogenetic diseases, said Rupert Sandbrink.

Dr. Hinsby joins the Board as an independent Director. He brings more than 15 years of experience as a biotech entrepreneur, executive and investor. Currently, he is the CEO of Muna Therapeutics and works as entrepreneur-in-residence with Novo Seeds. He co-founded and was the CEO of Orphazyme A/S from 2009 to 2019 and led the companys journey from University spin-out to a late-stage biopharmaceuticals company with a focus on rare diseases. Anders has a Ph.D. in Medicine from the University of Copenhagen.

It is an honour to join the Board of Vico. The company has promising programs in development for detrimental diseases of the CNS, an exciting RNA editing platform and a very experienced team in place to move the company forward. I look forward to taking part in its journey from discovery to becoming a leading CNS company., said Anders Hinsby.

Caption:Dr. Rupert Sandbrink, New CMO

For high resolution please click the image.

Caption:Dr. Anders Hinsby, New independent Board Member

For high resolution please click the image.

About Vico TherapeuticsVico Therapeutics is a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare severe neurological disorders. Vico's antisense oligonucleotide platform (AON) is focusing on different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD). Its early discovery RNA editing platform is directed towards RETT syndrome.Vico was founded in 2019 by highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.

Contacts

Vico Therapeutics B.V.Gertjan Bartlema, Chief Business Officer+31 (0)71 203 68 31This email address is being protected from spambots. You need JavaScript enabled to view it. http://www.vicotx.com

LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon Melens+31 6 538 16 427This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Huntington Disease; Rett Syndrome; RNA Editing; RNA; Oligonucleotides, Antisense; Spinocerebellar Ataxias; Rare Diseases; Nervous System Diseases; Biotechnology

Published by B3C newswire

Original post:
Dutch Vico Therapeutics Strengthens Leadership Team with the Appointment of Rupert Sandbrink as Chief Medical Officer and Anders Hinsby as Independent...

Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE 435 Against Helicobacter pylori Stomach Bacteria – BioSpace

Highlights:

SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce PharmaLtd (ASX: RCE), the Company developing New Classes of Synthetic Anti-Infectives, today announced it has entered into an agreement with the Murdoch Childrens Research Institute (MCRI) to conduct preclinical studies assessing the potential of RECCE 435 (R435) for the treatment of Helicobacter pylori (H. pylori) infections.

Antibiotic-resistant forms of H. pylori are on the rise, stated Recce Pharmaceuticals Non-Executive Chairman, Dr. John Prendergast. This is worrisome because more than four billion worldwide are infected with H. pylori,1 which is the leading cause of peptic ulcers and stomach cancer. We are excited to collaborate with Professor Sutton and MCRI in investigating the potential of our oral antibiotic RECCE 435 as what could be the first non-combination treatment for H. pylori infection, including those caused by drug resistant forms of the pathogen.

The research program will be carried out by the Mucosal Immunology Group at the MCRI, Royal Childrens Hospital. The MCRI is the largest child health research institute in Australia and one of the top three worldwide for research quality and impact.2

Researchers will evaluate the antimicrobial activity of RECCE 435 against H. pylori across a range of internationally recognized in-vitro and in-vivo study models. The studies will be led by Professor Philip Sutton, Head of MCRI Mucosal Immunology Group in Victoria, Australia. Professor Sutton recently joined Recces clinical advisory committee as Head of the H. pylori program with a world leading background in the biology of H. pylori and the subsequent infections linked to stomach ulcers and gastric cancer.

There is a global unmet medical need for the treatment of H. pylori with no first-line therapy curative in all patients.3 Today, the most commonly used treatment is triple therapy, which includes the use of a proton-pump inhibitor (PPI) in combination with multiple antibiotics (amoxicillin, metronidazole and/or clarithromycin).4 The existing treatment duration is 7 to 14 days; however, the eradication rate of standard triple therapy has fallen below 80% due to the increasing prevalence of antibiotic resistant strains worldwide.2

Recce and MCRI will work together on the oral antibiotic dosing program with a particular focus on optimal dosing and the effect of RECCE 435. The agreement is in place until 31 December 2022; however, the Company anticipates completion in approximately 12 months, at which time it will pursue a human clinical trial. The Company is well funded to support the study program following its recent successful capital raise. All intellectual property rights are retained by the Company.

The World Health Organization (WHO) lists H. pylori as a priority pathogen on its list of antibiotic-resistant bacteria that pose the greatest threat to human health. An expert led panel at the WHO identified that there is an urgent need to develop new antibiotics against H. pylori, which remains a significant cause of morbidity and mortality worldwide. As a result, the U.S. Food and Drug Administration have included H. pylori as a bacterium qualifying for their Qualified Infectious Disease Product (QIDP) program. The estimated direct and indirect costs related to H. pylori and peptic ulcer disease is nearly $6 billion annually.5

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327 and RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria including their superbug forms. Recces new antibiotic compound, RECCE 435, has been formulated for oral use.

The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Corporate ContactJames GrahamRecce Pharmaceuticals Ltd+61 (02) 8075 4585James.graham@recce.com.au

Media and Investor Relations (AU)Andrew GeddesCityPR+61 (02) 9267 4511ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)Meredith Sosulski, Ph.D.LifeSci Communications+1 929 469 3851msosulski@lifescicomms.com

__________________________________1 https://www.gastrojournal.org/article/S0016-5085(17)35531-2/pdf2 https://www.mcri.edu.au/about3 https://www.racgp.org.au/afp/2014/may/helicobacter-pylori-eradication/4 https://clinicaltrials.gov/ct2/show/NCT038324655 https://www.cdc.gov/mmwr/preview/mmwrhtml/00049679.htm

Read this article:
Recce Pharmaceuticals and Murdoch Children's Research Institute to Evaluate RECCE 435 Against Helicobacter pylori Stomach Bacteria - BioSpace